Your location:Home page > Program
David Bushinsky
Share the:
University of Rochester | Medicine

David A. Bushinsky, M.D.


David A. Bushinsky, is the John J. Kuiper Distinguished Professor of Medicine Emeritus and Professor of Pharmacology and Physiology at the University of Rochester School of Medicine.  He was the Chief of the Nephrology Division at the University of Rochester Medical Center for almost 3 decades.


Dr Bushinsky has published over three hundred peer-reviewed articles, invited reviews, chapters and editorials focusing on disorders of divalent ion metabolism.  His has developed a strain of rats that exhibit genetic hypercalciuria, the most common metabolic abnormality in humans with nephrolithiasis, and spontaneously form kidney stones.  The pathophysiolgy of the hypercalciuria closely parallels that of man and is thus a useful model to study stone formation in humans.  He has also extensively studied the mechanism by which metabolic acids induce physicochemical bone dissolution and cell-mediated bone resorption. His research has been consistently funded by grants from the National Institutes of Health for over 3 decades. Dr Bushinsky has lectured throughout the world on stone formation, effects of acid on bone and other disorders of divalent ion metabolism.


Dr Bushinsky received his medical degree from Tufts University School of Medicine in Boston, Mass. He completed an internship and residency at Tufts New England Medical Center Hospital in Boston, Mass. He also completed a fellowship in clinical nephrology and a research fellowship in nephrology at Tufts New England Medical Center Hospital in Boston, Mass.


Dr Bushinsky is a member of a number of organizations including the Association of American Physicians and the American Society for Clinical Investigation.

Attendance records:1

The lecture video:0





The academic assignments are as follows
Date (UTC+8) Time (UTC+8) Local Time Hall Session Role Talk Title
2022-06-17 15:15-15:30 2022-06-17,15:15-15:30Hall 3

Dietary Acid Load and Metabolic Acidosis – Overlooked Treatment Targets in CKD - Session 17

Speaker Correcting Metabolic acidosis in CKD - what evidence do we have? What's new on the Horizon?